香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 VISEN Pharmaceuticals 維昇藥業 （於開曼群島註冊成立的有限公司） （股份代號：2561） 截至2024年12月31日止年度 財務業績 本公告由維昇藥業（「本公司」，連同其附屬公司，統稱「本集團」）根據《香港聯合 交易所有限公司（「聯交所」）證券上市規則》（「《上市規則》」）第13.49(1)條的註刊 發。 本公司股東和有意投資者謹請注意，本集團截至2024年12月31日止年度的初步業 績（誠如《上市規則》第13.49(1)條所規定）已載入本公司日期為2025年3月13日的 招股章程附錄二B「截至2024年12月31日止年度的未經審計初步財務資料」，其可 於聯交所網站( www.hkexnews.hk )及本公司網站( www.visenpharma.com )查閱。 承董事會命 維昇藥業 執行董事兼首席執行官 盧安邦先生 香港，2025年3月27日 於本公告日期，本公司董事會包括(i ...

Investment Rating - The report assigns a "Neutral" rating with a total score of 69 out of 100 [3][14]. Core Insights - The company has a promising pipeline with products that, if approved, could meet significant demand in the Chinese market, particularly for conditions like Pediatric Growth Hormone Deficiency (PGHD) and Hypoparathyroidism [2][8][10]. - The company is positioned as the first endocrine drug manufacturer in the Hong Kong market, which may provide a competitive edge [14]. Industry Outlook - PGHD is prevalent among children under 18, accounting for 41.5% of short stature cases in China, with only 5.3% treatment rate in 2023, indicating a substantial unmet need [2]. - The market for achondroplasia treatment is currently limited, with only two products in clinical trials, suggesting a strong first-mover advantage for the company's product, Navepegritide [6]. - The demand for drugs treating Hypoparathyroidism is expected to grow, with the patient population projected to increase from 410,100 in 2023 to 495,600 by 2030 [7]. Company Operations - The company has not yet launched any products, resulting in no sales revenue. The net loss for shareholders in 2023 was approximately 250 million RMB, a 13.5% reduction year-on-year [8]. - Research and development costs have decreased significantly, contributing to the reduced net loss, while cash flow from operating activities remains healthy with no bank loans [8]. - The company has a robust pipeline with core products already approved in Europe and the U.S., with expectations for approval in China by 2025 [5][10]. Valuation Level - The company's valuation is considered reasonable, with a market capitalization range of 77.0 to 84.6 billion HKD, slightly lower than comparable companies in the biotech sector [10][12]. - The price-to-book ratio for the company's IPO price is estimated at 18.3 to 20.2 times, which is competitive compared to peers [10]. Market Sentiment - The recent market atmosphere has improved, with a higher percentage of newly listed companies experiencing price increases on their debut [13]. - The presence of notable cornerstone investors, such as WuXi Biologics, indicates confidence in the company's research capabilities [14].

Investment Rating - The report assigns a "Neutral" rating with a total score of 69 out of 100 [3][14]. Core Insights - The company has a promising pipeline with products that, if approved, could meet significant demand in the Chinese market, particularly for conditions like Pediatric Growth Hormone Deficiency (PGHD) and others [2][6][8]. - The company is positioned as the first endocrine drug manufacturer in the Hong Kong market, which may provide a competitive edge [14]. Industry Outlook - PGHD is prevalent among children under 18, with 41.5% of the total short stature cases in this age group in China. The treatment rate for this condition is currently low at 5.3%, indicating a substantial unmet need [2]. - The company’s product, Lonapegsomatropin, is the first long-acting growth hormone approved in the US and Europe, with expectations for approval in China by 2025 [5][8]. - There is a lack of approved drugs for Achondroplasia in China, with only the company’s Navepegritide and Sanofi's SAR442501 in clinical trials, suggesting a strong first-mover advantage if successful [6]. - For Hypoparathyroidism, the market is expected to grow from 410,100 cases in 2023 to 495,600 by 2030, highlighting a significant demand for effective treatments [7]. Company Operations - The company has not yet launched any products, resulting in no sales revenue. The net loss for shareholders in 2023 was approximately 250 million RMB, a 13.5% decrease year-on-year, primarily due to reduced R&D costs [8]. - The company’s cash flow from operating activities has remained stable, with net cash used in operations of 270 million RMB in 2023 and 100 million RMB in the first half of 2024 [8]. - The company has no bank borrowings, indicating a healthy balance sheet despite the absence of product approvals [8]. Valuation Level - The company’s valuation is considered reasonable, with a market capitalization range of 77.0 to 84.6 billion HKD, slightly lower than comparable companies in the biotech sector [10]. - The price-to-book ratio for the company is projected to be between 18.3 and 20.2 times, which is competitive compared to peers [10]. Market Sentiment - Recent market conditions have improved, with 14 out of 19 newly listed companies experiencing price increases on their first trading day, indicating a favorable environment for new listings [13].